Reprogenix Bio

Reprogenix Bio is a San Diego-based biotechnology company focused on developing next-generation oncolytic virus therapies for the treatment of solid tumors. The company utilizes its proprietary Repro-V platform to engineer highly selective and potent viral vectors, primarily based on Herpes Simplex Virus (HSV), designed to replicate within cancer cells and trigger a systemic anti-tumor immune response. By combining viral oncolysis with immune-stimulating payloads, Reprogenix Bio aims to transform the tumor microenvironment and improve outcomes for patients who are non-responsive to current immunotherapies. The leadership team brings extensive experience from pioneering oncolytic virus programs, including the development of the first FDA-approved oncolytic therapy, T-VEC.